Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence

Molecularly imprinted hybrid adsorbents for adenine and adenosine-5'-triphosphate

Submicrometer-sized silica gel particles were coated with a polyanion and a polycation bearing thymine chromophores. The polymer-coated particles were found to selectively adsorb adenine and adenosine-5'-triphosphate (ATP), as compared to other nucleobases and nucleotides, respectively. The adsorption was enhanced by the irradiation of the particles in the presence of adenine which resulted in the molecular imprinting of adenine. ATP adsorption was strongly pH-dependent.

Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro

BACKGROUND

Capecitabine, an oral anticancer prodrug, was associated with relatively mild degrees of side effects, notably low myelosuppression. Previous studies demonstrated capecitabine monotherapy as safe and very useful for recurrent and advanced metastatic breast cancer patients who are generally associated with a poor prognosis.

MATERIALS AND METHODS

Capecitabine and two conventional cytotoxic antineoplastic drugs (epirubicin and docetaxel) were employed in this study in order to compare their therapeutic antineoplastic effects. The tumour tissues obtained from 42 patients and breast carcinoma cell lines were treated with the chemotherapeutic agents above in vitro. Their efficacy was determined using ATP Bioluminescence assay which measures the metabolic rate, WST-1 assay that could quantify the inhibition of cell proliferation and immunohistochemical studies. The proapoptotic effects was examined using in situ apoptosis kit.

RESULTS

Both solid tumour and cell lines treated by capecitabine as well as two drugs above demonstrated a significant decrement in metabolic and proliferation rates. However, capecitabine treatment resulted in significant increment of the number of the tumour cells undergoing apoptosis.

CONCLUSION

Results of our present study demonstrated that capecitabine could be a useful agent against breast cancer cells with less side effects and its inhibition of cell proliferation of breast carcinoma is at least similar to that of two other commonly used cytotoxic drugs.

A new predictive and prognostic marker (ATP bioluminescence and positron emission tomography) in vivo and in vitro for delivering adjuvant treatment plan to invasive breast tumor patients

The cell proliferation rate has been used to assess the biological aggressiveness and the metastatic potential of breast carcinoma. Different methods (flow cytometric S phase and proliferation associated antigens) have been used to assess the rate of proliferation previously. In this preliminary study, the cell proliferation rate of normal (N=45), benign (N=29) and invasive breast tumor tissue (N=70) has been quantified in vitro by ATP bioluminescence assay. Next, individual prognostic factor (tumor grades, lymph node involvement, estrogen and progesterone receptor and HER-2 status) has been correlated with the level of metabolic rate (ATP). The results showed that invasive tumor had the highest level of ATP bioluminescence compared with that of benign tumor (mean difference=1.97) and the normal breast tissue (mean difference=2.75). In addition, ATP level positively correlated with the number of axillary lymph node involvement (r(spearman)=0.433, P=0.021). These findings suggested that the measurement of ATP level may serve as a mean for the detection of cell proliferation and hence a surrogate marker for disease prognosis.

The efficacy of Paclitaxel on solid tumour analysed by ATP bioluminescence assay and VEGF expression: a translational research study

BACKGROUND

Paclitaxel (Taxol), is known to induce mitotic arrest and apoptosis by inhibiting the depolymerisation of microtubules. Tumour growth and metastasis are affected by the metabolic rate and angiogenesis. We investigated the effect of Paclitaxel on tumour metabolism and markers of angiogenesis, vascular endothelial growth factor (VEGF).

MATERIALS AND METHODS

Tissue samples of 39 patients diagnosed with invasive carcinoma were obtained. The solid tumours were cultured with Paclitaxel at a concentration of 4.27 ug/ml for 24 h. The metabolic rate of the samples was measured by ATP Bioluminescence assay and the levels of VEGF in culture medium were measured by ELISA.

RESULT

The mean ATP concentration of control and test groups were 7.169 and 5.004 rlu/ml, respectively, suggesting that the metabolic rate was inhibited by Paclitaxel. The mean VEGF levels in the control and test groups were 5.335 and 4.567 pg/ml, respectively. All data analysed were statistically significant (P < 0.005). The finding of the study showed that Paclitaxel could inhibit metabolic rate in solid tumour. It could also downregulate VEGF.

CONCLUSION

Our result suggested that Paclitaxel is an effective cytotoxic possibly with anti-angiogenic effects.